LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC

References

• Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411(6835):355–365. doi:10.1038/35077225
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–566. doi:10.1038/nature05945
   PubMed Web of Science ®Google Scholar
• Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131(6):1190–1203. doi:10.1016/j.cell.2007.11.025
   PubMed Web of Science ®Google Scholar
• Ju YS, Lee WC, Shin JY, et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 2012;22:436–445. doi:10.1101/gr.133645.111
   PubMed Web of Science ®Google Scholar
• Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012;18(3):375–377. doi:10.1038/nm.2644
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18(3):378–381. doi:10.1038/nm.2658
   PubMed Web of Science ®Google Scholar
• Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012;18(3):382–384. doi:10.1038/nm.2673
   PubMed Web of Science ®Google Scholar
• Choudhury NJ, Drion A. Decade in review: a new era for RET-rearranged lung cancers. Transl Lung Cancer Res. 2020;9(6):2571–2580. doi:10.21037/tlcr-20-346
   PubMed Web of Science ®Google Scholar
• Drilon A, Lin JJ, Filleron T, et al. Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET-rearranged lung cancers. J Thorac Oncol. 2018;13(10):1595–1601. doi:10.1016/j.jtho.2018.07.004
   PubMed Web of Science ®Google Scholar
• Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N Engl J Med. 2020;383(9):813–824. doi:10.1056/NEJMoa2005653
   PubMed Web of Science ®Google Scholar
• Drilon A, Subbiah V, Gautschi O, et al. Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 Phase I/II trial. J Clin Oncol. 2023;41(2):385–394. doi:10.1200/JCO.22.00393
   PubMed Web of Science ®Google Scholar
• Lau SCM, Ou SH. Selpercatinib as the guardian of the central nervous system for patients with RET fusion-positive NSCLC? J Thorac Oncol. 2023;18(5):561–563. doi:10.1016/j.jtho.2023.02.005
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Zhou CC, Drilon A, et al. Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer. Future Oncol. 2021;17(7):763–773. doi:10.2217/fon-2020-0935
   PubMed Web of Science ®Google Scholar
• Gandi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–2092. doi:10.1056/NEJMoa1801005
   PubMed Web of Science ®Google Scholar
• Zhu VW, Klempner SJ, Ou SI. Receptor tyrosine kinase fusions as an actionable resistance mechanism to EGFR TKIs in EGFR-mutant non-small-cell lung cancer. Trends Cancer. 2019;5(11):677–692. doi:10.1016/j.trecan.2019.09.008
   PubMed Web of Science ®Google Scholar
• Zhou C, Solomon B, Loong HH, et al. First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive. NSCLC N Engl J Med. 2023;389(20):1839–1850. doi:10.1056/NEJMoa2309457
   PubMed Web of Science ®Google Scholar
• Mok TSK, Nakagawa K, Park K, et al. LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722. Ann Oncol. 2022;33(supplement 9):S1561–S1562. doi:10.1016/j.annonc.2022.10.350
   Google Scholar
• Yang JCH, Lee DH, Lee JS, et al. Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study. J clin oncol. 2023;41(17_suppl:LBA9000. doi:10.1200/JCO.2023.41.17_suppl.LBA9000
   Web of Science ®Google Scholar
• Zhao W, Jiang W, Wang H, He J, Su C, Yu Q. Impact of smoking history on response to immunotherapy in non-small-cell lung cancer: a systematic review and meta-analysis. Front Oncol. 2021;11:703143. doi:10.3389/fonc.2021.703143
   PubMed Web of Science ®Google Scholar
• Brazel D, Ou SI. The additional exclusions of ROS1 fusions (In Addition to EGFR Mutation and ALK Fusions) in the cemiplimab NSCLC FDA indication (EMPOWER-Lung 1 and -Lung 3). catching up with current scientific view of immunotherapy in never-smoker predominant actionable driver mutation positive NSCLC? Lung Cancer. 2023;14:63–69. doi:10.2147/LCTT.S413611
   PubMed Web of Science ®Google Scholar
• Gainor JF, Curigliano G, Kim DW, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, Phase 1/2 study. Lancet Oncol. 2021;22(7):959–969. doi:10.1016/S1470-2045(21)00247-3
   PubMed Web of Science ®Google Scholar
• Griesinger F, Curigliano G, Thomas M, et al. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. Ann Oncol. 2022;33(11):1168–1178. doi:10.1016/j.annonc.2022.08.002
   PubMed Web of Science ®Google Scholar
• Drugs.com. FDA Grants Regular Approval for Gavreto (pralsetinib) for Non-Small Cell Lung Cancer with RET Gene Fusions. Available from: https://www.drugs.com/newdrugs/fda-grants-regular-approval-gavreto-pralsetinib-non-small-cell-lung-cancer-ret-gene-fusions-6084.html. Assessed December 31, 2023.
   Google Scholar
• Popat S, Felip E, Kim ES, et al. AcceleRET Lung: a phase 3 study of first-line pralsetinib in patients with RET fusion–positive advanced/metastatic NSCLC. J clin oncol. 2022;40(16_suppl):TPS9159. doi:10.1200/JCO.2022.40.16_suppl.TPS9159
   Web of Science ®Google Scholar
• Wu YL, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383(18):1711–1723. doi:10.1056/NEJMoa2027071
   PubMed Web of Science ®Google Scholar
• Tsuboi M, Herbst RS, John T, et al. Overall survival with osimertinib in resected EGFR-mutated NSCLC. N Engl J Med. 2023;389(2):137–147. doi:10.1056/NEJMoa2304594
   PubMed Web of Science ®Google Scholar
• Wu YL, Dziadziuszko R, Ahn JS, et al. Alectinib in resected ALK-positive non-small-cell lung cancer. N Engl J Med. 2024;390(14):1265–1276. doi:10.1056/NEJMoa2310532
   PubMed Web of Science ®Google Scholar
• Ou SH, Bartlett CH, Mino-Kenudson M, Cui J, Iafrate AJ. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist. 2012;17(11):1351–1375. doi:10.1634/theoncologist.2012-0311
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Tan L, Lin JJ, et al. RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies. J Thorac Oncol. 2020;15(4):541–549. doi:10.1016/j.jtho.2020.01.006
   PubMed Web of Science ®Google Scholar
• Rosen EY, Won HH, Zheng Y, et al. The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers. Nat Commun. 2022;13(1):1450. doi:10.1038/s41467-022-28848-x
   PubMed Web of Science ®Google Scholar
• Duke ES, Bradford D, Marcovitz M, et al. FDA approval summary: selpercatinib for the treatment of advanced RET fusion-positive solid tumors. Clin Cancer Res. 2023;29(18):3573–3578. doi:10.1158/1078-0432.CCR-23-0459
   PubMed Web of Science ®Google Scholar